

**Contact:**

Anthony Recupero, Ph.D.  
Vice President Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

***MaxCyte to Present at AABB Annual Meeting & TXPO 2008 in  
Montréal, Québec, Canada***

***“Peripheral Blood Mononuclear Cells Engineered with mRNA Encoding Chimeric Tumor Antigen  
Receptor for Cancer Therapy” AND “Use of Platelets as Therapeutic Delivery Vehicles”***

**Gaithersburg, MD, October 3, 2008** – MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Joseph C. Fratantoni, MD, Vice President Medical Affairs and Clinical Development at MaxCyte, will give two presentations at the AABB Annual Meeting & TXPO in Montreal, Canada to be held October 4-7, 2008.

Dr. Fratantoni’s first presentation is entitled, “Peripheral Blood Mononuclear Cells Engineered with mRNA Encoding Chimeric Tumor Antigen Receptor for Cancer Therapy” (Abstract # S45-020F) and will be held during the “Cell Therapies: Clinical Applications” session from 4:00 – 5:30 pm on October 5, 2008 in the Palais des Congres de Montreal, Room 51. The presentation will discuss how chimeric tumor-antigen receptor mRNA loaded peripheral blood mononuclear cells offer the potential to develop customizable, engineered outpatient transfusion medicine products for cancer therapies without the infrastructure and logistical challenges associated with development of traditional cellular therapy products.

Dr. Fratantoni’s second presentation will describe the “Use of Platelets as Therapeutic Delivery Vehicles” and take place on October 5 from 5:30 – 6:30 pm during the abstract poster reception as well as during poster Session II: Platelet and Leukocyte Biology taking place from 7:30 am Monday, October 6 through noon on Tuesday, October 7 in Hall 220E of the Palais des Congres de Montreal. This presentation will discuss how platelets can be safely and effectively loaded with therapeutics, such as siRNA, to take advantage of their natural homing properties in vivo.

**About MaxCyte**

MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte’s cell transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

MaxCyte’s licenses its cell modification technology to companies developing cell-based therapies and sells instruments and disposables to leading biopharmaceutical companies for drug discovery. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than a dozen

commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER). Building on its core technology and relationships, new opportunities are being pursued in the development of first-in-class targeted therapies for cancer, autoimmune and infectious diseases. MaxCyte intends to develop these programs to the proof-of-concept stage and then enter into co-development agreements with biopharmaceutical companies.

**For more information, visit <http://www.maxcyte.com>.**

###